- ProBioGen has signed a Master Service Agreement with Zag Bio to provide integrated CDMO services for the ZAG-101 biologic programme.
- The agreement covers cell line development, process development, and GMP manufacturing ahead of planned clinical entry in H2 2026.
ProBioGen has announced the signing of a Master Service Agreement (MSA) with Zag Bio, Inc., a biotechnology company developing thymus-targeted therapies designed to induce central immune tolerance. Under the first integrated service package of the agreement, ProBioGen will support Zag Bio’s lead product candidate, ZAG-101, which is being developed for the prevention or delay of Type 1 diabetes.
The CDMO will provide cell line development, process development, and GMP manufacturing services to prepare ZAG-101 for clinical development, which is targeted to begin in the second half of 2026. Cell line development will be based on ProBioGen’s CHO.RiGHT® expression platform, using its DirectedLuck® transposase technology and PsiBot smart automation solution to support efficient clone selection and robust manufacturing performance.
According to the companies, the development strategy includes parallel assessment of multiple candidate constructs to enable data-driven selection of the optimal clinical candidate while maintaining an accelerated development timeline. The approach is intended to support early risk mitigation while establishing a scalable foundation aligned with regulatory and quality requirements.
“This agreement is more than a contractual milestone. It marks the beginning of a collaborative effort to bring Zag Bio’s highly innovative thymus-targeted bifunctional antibody program to life.”
Dr Alfred Merz, Chief Executive Officer at ProBioGen
The MSA brings together ProBioGen’s integrated development and contract manufacturing capabilities with Zag Bio’s antibody-based therapeutic programme, creating a streamlined path to support clinical advancement and future scale-up of ZAG-101 and related autoimmune disease candidates.
